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Abstract: One of the major hurdles to cure cancer lies in the
low potency of currently available drugs, which could eventu-
ally be solved by using more potent therapeutic macromole-
cules, such as proteins or genes. However, although these
macromolecules possess greater potency inside the cancer
cells, the barely permeable cell membrane remains a formi-
dable barrier to exert their efficacy. A widely used strategy is
to use cell penetrating peptides (CPPs) to improve their intra-
cellular uptake. Since the discovery of the first CPP, numer-
ous CPPs have been derived from natural or synthesized
products. Both in vitro and in vivo studies have demon-
strated that those CPPs are highly efficient in transducing car-
goes into almost all cell types. Therefore, to date, CPPs have
been widely used for intracellular delivery of various cargoes,
including peptides, proteins, genes, and even nanoparticles.
In addition, recently, based on the successes of CPPs in cellu-
lar studies, their applications in vivo have been actively pur-
sued. This review will focus on the advanced applications of
CPP-based in vivo delivery of therapeutics (e.g., small mole-
cule drugs, proteins, and genes). In addition, we will high-
light certain updated applications of CPPs for intracellular
delivery of nanoparticulate drug carriers, as well as several
“smart” strategies for tumor targeted delivery of CPP-
cargoes. VC 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A:
102A: 575–587, 2014.
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INTRODUCTION
In the past decades, numerous biomaterials have been
newly developed and drawn enormous interest for their
potential use in a wide variety of ﬁelds, encompassing medi-
cine, biology, chemistry, and tissue engineering.1,2 To date,
one of the speciﬁc ﬁelds that those biomaterials have made
a signiﬁcant impact is the cancer therapy. The intervention
of biocompatible peptides [e.g., cell penetrating peptides
(CPPs)], proteins, biopolymers, and various nanocomposites
in delivery of anticancer drugs has revolutionized the para-
digm of drug delivery.3–6
The ﬁrst record of cancer can be traced to an Egyptian
papyrus dating back to about 3000 B.C.7 Although cancer
has been known for much of our recorded history, an effec-
tive cure for this life-threatening disease is yet to be found.
Efforts during the past century have led to enormous advan-
ces in our understanding of cancer pathogenesis, detection
techniques, surgical methods, and also the development of
anticancer drugs. Despite these advances, the primary treat-
ment of cancer has yet been limited to chemotherapy
intended for relief of pain or extension of life span, espe-
cially for metastatic cases. A major hurdle for treatment of
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cancer by current anticancer drugs lies in the poor efﬁcacy
and inadvertent systemic toxicity caused by the narrow
therapeutic window of these drugs. To this regard, drug
delivery systems (DDS) have been pursued to address the
toxicity issue, and signiﬁcant progress has been made in
this area, resulting in the approval of several DDS formu-
lated drugs for clinical applications. The second thrust of
effort, meanwhile, has been concentrated on the search for
new drug entities with greater efﬁcacy. To this issue, macro-
molecules (e.g., protein, peptides, or genes) have gained
enormous interest due to their unmatched potency and
speciﬁcity as compared to current anticancer drugs. The
delivery of these macromolecular drugs; however, remains a
formidable challenge. Many of these macromolecular drugs
act upon speciﬁc processes found within the cell, which
require internalization of the molecules and their delivery
to appropriate cellular compartments. Yet, the greater size
and lower lipophilicity of macromolecular drugs, compared
to small molecule counterparts, hinders their efﬁcient cellu-
lar internalization.
An interesting ﬁnding made by Frankel and Pabo in
1988 was that transcription transactivating protein (TAT)
derived from HIV virus has the ability to penetrate cellular
membranes.8 This discovery was a prelude to the identiﬁca-
tion and characterization of various cell penetrating pep-
tides (CPPs) that possess the ability to enter cells. More
interestingly, it was later found that the coupling of CPPs to
different cargoes (e.g., small molecules, peptides or proteins,
genes, or nanoparticles) enabled efﬁcient internalization of
these cargoes into cells.9–13 The discovery of CPPs and their
ability to ferry cargoes into cells has produced a revolution-
ary impact on the development of macromolecule-and nano-
particle-based treatments.
In this review, we will brieﬂy discuss the nature of vari-
ous CPP-mediated drug delivery, as well as the suggested
mechanisms for their cellular uptake. We will then look at
the application of the CPPs for cancer treatment, focusing
speciﬁcally on advanced in vivo studies, followed by discus-
sing a few “smart” strategies for targeted delivery of
CPP-cargoes.
CELL PENETRATING PEPTIDES
CPPs, also known as protein transduction domains (PTDs),
are a group of peptides sharing several common characteris-
tics as follows.14–16 First, they are peptides consisting of
less than 35 amino acid residues. Second, they can efﬁ-
ciently internalize into cells and also carry coupled cargoes
into cells with them. Furthermore, they do not pose any
reported cytotoxicity. The peptides, which fall in this cate-
gory, originate from a wide variety of sources (e.g., humans,
mice, viruses, or synthesis). On the basis of their structural
characteristics, CPPs can be simply divided into two classes:
arginine-rich CPPs and amphipathic CPPs.17
Arginine rich CPPs
Commonly explored arginine-rich CPPs include TAT peptide
(TATp), oligoarginine, penetratin, low molecular weight prot-
amine (LMWP), and pVEC.10,18–21 It is widely believed that
the basic arginine and lysine residues of these peptides play
a crucial role in the cell internalization process.
TATp is an 11-mer peptide (YGRKKRRQRRR) derived
from the transcription TAT encoded by human immunodeﬁ-
ciency virus Type 1 (HIV-1). A study of TATp (47–57) in
1998 revealed this to be the minimum TAT protein length
that retained the cell entry capability.18 Since then, the TATp
has become one of the most extensively studied
CPPs.13,15,22,23
Since the initial discovery of TATp, various researches
have elucidated the critical role of cationic amino acids (i.e.,
arginine, lysine, and histidine) in the cell entry of TATp. Fur-
ther studies have shown that oligoarginines composed of
8–10 arginine residues (Arg) can also efﬁciently internalize
into cells.19 It was found that among the cationic amino
acids, arginine possessed the greatest potential for cell pen-
etration, possibly attributed to its more basic nature (pKa
12.5) and the formation of strong hydrogen bonds between
the guanidine groups and anionic glycosaminoglycans on
the cell membrane.24 Interestingly, it has also been demon-
strated that nona-arginine (RRRRRRRRR) is the most
efﬁcient oligoarginine for the cell entry.19,25 Further mecha-
nistic studies showed that D-isoform and even the branched
forms of oligoarginine retained the cell penetrating ability,
which suggested the possible involvement of receptor-
independent cell entry pathways.19
LMWP is a 14-mer peptide (VSRRRRRRGGRRRR) derived
by thermolysin-mediated digestion of protamine.20 Com-
pared with TATp, LMWP retains similar CPP motif in struc-
ture and has shown equivalent cell penetrating activity.
However, LMWP possesses several important and attractive
characteristics as compared to other CPPs, such as: (1) efﬁ-
cient mass production by simple enzymatic digestion of nat-
ural protamine; (2) proven low toxicity and immunogenicity
in animal model studies; and (3) ensured safety as it origi-
nates from protamine, a widely used clinical heparin anti-
dote.20 LMWP has been successfully utilized to translocate
various cargos into different types of cells.20,26–29
While TAT protein was the ﬁrst identiﬁed cell permeable
protein, the ﬁrst CPP discovered was penetratin. Penetratin
is a 16-mer peptide (RQIKIWFQNRRMKWKK) present in the
third helix of Antennapedia homeodomain.4 Homeoproteins
are a class of transcription factors that bind DNA through a
60 amino acid length homeodomain composed of three
a-helices and a b-turn. Studies have shown that arginine
and lysine residues are important for the cellular translocal-
ization of penetratin.10 Also, tryptophan residues (Trp48
and 56) are reported to play an important role in the initia-
tion of the translocation.10,30,31 Since the discovery of pene-
tratin, a number of studies have been designed to use this
CPP for delivery of various cargoes, including small mole-
cules, proteins, oligonucleotides, peptide nucleic acid (PNA),
and nanoparticles.32–34
pVEC, an 18-mer peptide (LLIILRRRIRKQAHAHSK) cor-
responding to residues (615–632) of the murine vascular
endothelial cadherin (VE-cadherin), has been shown to
translocate into various cell lines, even including the plant
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cells.21 A nonendocytic pathway for the cell entry has been
proposed, as the rate of translocation is not affected by tem-
perature or endocytosis inhibitors.21 Interestingly, pVEC was
found to also possess antimicrobial activity at micro-molar
concentrations.35
Amphipathic CPPs
Amphipathic CPPs are structurally distinguished from
arginine-rich CPPs in that they have fewer, or completely
lack of arginine residues and in that they are amphipathic
in nature. Amphipathicity and lysine residues are considered
to play a crucial role in the cellular translocation of this
class of CPPs. They can be further divided into 2 groups:
(1) peptides with primary amphipathicity (e.g., transportan,
MPG, and pep-1)—having distinct hydrophobic and hydro-
philic domains separately located in the peptide
sequence;36–38 and (2) peptides with secondary amphipa-
thicity (e.g., MAP)—having an a-helix structure with polar
and nonpolar residues located on the opposite sides.39
Transportan, a 27-mer chimeric peptide (GWTLNSA-
GYLLGKINLKALAALAKKIL) composed of 13 N-terminal resi-
dues of galanin neuropeptide with substitution of proline to
lysine at 13th amino acid and 14 residues of mastoparan
peptide from wasp venom, is able to translocate green ﬂuo-
rescence protein, antibody, or gold particles into cells.36
Interestingly, a truncated form of transportan named TP10
(AGYLLGKINLKALAALAKKIL) was also found to possess
equivalent cell penetrating ability to the parent transpor-
tan.40 EL-Andaloussi et al. showed that a hybrid of TP10
and peptide nucleic acid (PNA), conjugated with a double
stranded oligodeoxynucleotide against a transcription factor,
Myc, was efﬁciently taken up by mouse neuroblastoma cells
(N2a) and human breast cancer cells (MCF-7).41
Both the 27-mer MPG peptide (GALFLGFLGAAGSTM-
GAWSQPKKKRKV) and the 21-mer pep-1 peptide (KETW-
WETWWTEWSQPKKKRKV) are chimeric peptides with
primary amphipathicity constructed of an N-terminal hydro-
phobic region and a C-terminal hydrophilic domain contain-
ing the nuclear localization signal (PKKKRKV) of the SV40
large T antigen. The hydrophobic region of MPG originates
from HIV-gp41 coat protein and that of pep-1 consists of a
tryptophan rich domain.37 It was suggested that the hydro-
phobic residues may contribute to the peptide’s interaction
with, and destabilization of the cellular membrane. A trun-
cated MPG (MPG-8: b-AFLGWLGAWGTMGWSPKKKRK-Cys-
teamide) was also reported to have the CPP activity.37,38
Model amphipathic peptide (MAP) is an 18-mer peptide
(KLALKLALKALKAALKLA) with secondary amphipathicity.
Through mechanistic in vitro studies, MAP has been shown
to internalize into cells by a nonendocytic pathway,42 and
has successfully been used to deliver PNA into cells.43 Inter-
estingly, it was found that MAP’s cell-internalization ability
was retained even after depriving of its amphipathicity.42
CELL ENTRY MECHANISM OF CPPs
While the mechanism of CPP-mediated cell entry has been
the subject of a large number of studies, there is still no
consensus on the mechanism of this translocation process.
A pioneering mechanism appeared to be a passive, energy-
independent process that was not sensitive to endocytosis
inhibitors.19,21,44 Recent studies re-evaluating the cellular
entry mechanisms of CPPs or CPP-cargoes; however, have
indicated the involvement of endocytosis.45 It has been sug-
gested that properties of CPPs (e.g., amphipathicity or
charge delocoalization) and the attached cargoes can affect
the cell entry pathway.46,47 Cell lines and incubation condi-
tions have also been shown to affect the cell entry of
CPPs.48 This review will brieﬂy discuss two major intracellu-
lar uptake mechanisms of CPPs: the energy-independent (non-
endocytosis) pathways and the endocytic pathways. These
CPP internalization pathways are illustrated in Figure 1.
Energy independent pathways
Different energy independent cell entry pathways for CPPs/
CPP-cargoes have been suggested, such as the (1) inverted
micelle model,49–51 (2) pore formation model,52 (3) carpet
model,53,54 and (4) membrane thinning model.55 The ﬁrst
step in all of these models requires the positively charged
CPPs to interact with the negatively charged components of
the cell membrane, such as heparan sulfate (HS) and the
phospholipid bilayer. Binding of the CPPs on the lipid
bilayer then leads to temporary destabilization of the
plasma membrane. Subsequent steps in the internalization
process vary depending upon the type and concentration of
CPPs, cargoes, cell lines, and incubation conditions.
The inverted micelle model was proposed based on
NMR studies of the interaction of penetratin with phospho-
lipid membranes. According to the hypothesized mechanism,
the positively charged CPP interacts with the negative heads
of the membrane phospholipids, followed by a reorganiza-
tion of the lipid bilayer and membrane shuttling aided by
interactions of the hydrophobic residues of the CPP with
the membrane. Subsequently, the CPP moves into the
bilayer while being entrapped in an inverted micelle, result-
ing in the move of this micelle to the opposite side of the
bilayer and release of its contents directly into the cytosol.
FIGURE 1. Schematic illustration of cell entry mechanism of CPPs.
Reproduced with permission from Ref. 23. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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Because this model assumes the involvement of the hydro-
phobic residues of CPPs in the formation of the inverted
micelle, it cannot be used to describe the translocation of
CPPs that have no hydrophobic segments (e.g., TATp and oli-
goarginines). Moreover, Lewin et al.,56 based on their stud-
ies with CPP-conjugated iron oxide nanoparticles (45 nm),
raised serious doubts on the formation of such “inverted
micelles.” Additionally, the inverted micelle structures have
not been visualized microscopically.
The pore formation model, also called the barrel-stave
model, describes one way in which antibacterial peptides
weaken the bacterial membrane, which is followed by depo-
larization of the membrane. Pore formation is the result of
bundles formed by the amphipathic a-helical structure of
CPPs. In this arrangement, outwardly facing hydrophobic
residues interact with the lipid membrane, while hydrophilic
groups form a central lumen to create the pore.
The carpet model was described as a model for translo-
cation of some antimicrobial peptides, but was also applied
to describe CPP toxicity at higher concentrations.53,54 In the
carpet model, positively charged CPPs, monomeric, or oligo-
meric, cover the negatively charged membrane in a carpet-
like manner, which results in a change in the CPP secondary
structure as the basic residues turn towards the membrane
surface and the hydrophobic residues interact with the
hydrophobic membrane core. When a concentration thresh-
old is reached, the CPP permeates the membrane by locally
disrupting the bilayer structure. Although this model has
been suggested for CPP translocation, its dependence on
hydrophobic residues seems to generate some controversy
since most CPPs are primarily basic and hydrophilic.
An alternative to the carpet model is the so-called
“membrane-thinning” effect, which was ﬁrst suggested for a
peptide toxin, magainin.55 In this model, following carpet
formation by CPPs, perturbation caused by charge interac-
tion in the outer leaﬂet results in a lateral rearrangement of
negatively charged lipids, followed by a thinning of the
membrane. Interaction, or aggregation, of CPPs on the mem-
brane surface produce a reduction of the local surface ten-
sion and allows CPPs to intercalate within the membrane.
The membrane then reseals after internalization of CPPs
onto intracellular targets.
Although all these mechanisms explain certain aspects
of membrane translocation by CPPs, none of them has pro-
vided a satisfactory or complete description of the internal-
ization pathway applicable to all types of CPPs. Moreover,
none of these models adequately predicts the cellular
uptake of large cargoes (up to 100-fold their own size)
mediated by these CPPs.
Endocytosis
Endocytosis, including phagocytosis and pinocytosis,57,58 is
a highly regulated process of internalization of solutes and
ﬂuids in the extracellular matrix. Phagocytosis is a complex
process used to uptake large particles and pinocytosis is
mainly used to bring in smaller particles. This pinocytosis
can be further classiﬁed into four different pathways: (1)
clathrin-mediated, (2) caveolae/lipid raft-mediated, (3) cla-
thrin and caveolae-independent endocytosis, and (4) macro-
pinocytosis.59–61
According to most of the initial mechanistic studies, the
cellular uptake of CPPs was considered to follow a nonendo-
cytic pathway. Later studies, however, showed that experi-
mental artifacts could affect the study results.59 For
instance, the ﬁxation of cells with methanol/formaldehyde
could allow the redistribution of the CPPs bound on the cell
surface, but not internalized. With further studies, there are
now some agreements on the involvement of various types
of endocytosis during the cell entry of CPPs or CPP-
cargoes.40,62
The endocytosis pathway for a particular CPP seems to
strongly depend on its properties as well as that of the con-
jugated cargoes (type, size, charge, or/and hydrophobicity).
For example, TATp has been shown to enter cells via lipid
raft-mediated endocytosis when conjugated to a protein, but
through a clathrin-dependent endocytosis when the cargo
was a ﬂuorophore. When conjugated to large cargoes (MW
>30 kDa), the CPP-cargoes entered cells via macropinocyto-
sis. Macropinocytosis is an actin-dependent form of endocy-
tosis that can occur in all cell lines at different
rates.60,61,63,64 It is distinguished from other types of endo-
cytic pathways by the membrane rufﬂing event and the size
of the vesicles formed.
APPLICATION OF CPPs AS DELIVERY VEHICLES FOR
CANCER THERAPY
CPP-based drug delivery has been explored to treat various
diseases, including neuronal disease, asthma, ischemia, dia-
betes, and cancer.22,65–67 There are currently more than
300 published studies related to CPP-based drug deliv-
ery.15 The most principal application among all studies has
been the cancer. As an efﬁcient carrier, the CPP has been
shown to successfully deliver cytotoxic drugs (e.g., small
anticancer drugs, toxins, tumor suppressor proteins, siRNA,
etc.) into tumor cells to induce apoptosis.11,20,23,68 Despite
the success reported through in vitro studies, only a few
studies have shown treatment efﬁcacy in animal models.
Here, we cover a few of the in vivo works conducted using
CPPs to treat cancers. Additionally, recent progress in CPP-
coupled intracellular delivery of nanoparticles is brieﬂy
mentioned.
CPP-coupled delivery of small molecule drugs
While small molecule anticancer drugs generally diffuse
into tumor cells with great efﬁciency due to their small
size and lipophilicity, there is a frequent occurrence of
multidrug resistance (MDR) after repeated exposure of
tumor cells to the same drugs.69 To overcome this prob-
lem, studies have explored the coupling of these drugs
with CPPs. For an example, Dubikovskaya et al. conjugated
octaarginine (R8) to taxol, an anticancer drug, via a disul-
ﬁde bond, which displayed the effect of preferentially
releasing taxol inside the cells.70 Both R8-taxol and taxol
alone were tested against ovarian cancer models with
OVCA-429 (taxol-sensitive) or OVCA-429T (taxol-resistant)
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cells implanted in the peritoneal cavity of mice. According
to their results, R8-taxol and taxol had similar effects
against taxol-sensitive tumors. However, when tested
against a taxol-resistant tumor model, R8-taxol treated
mice had signiﬁcantly higher survival rates as compared
with mice treated with taxol alone. Interestingly, this study
showed several more merits of coupling small molecule
drugs with CPP, aside from the potential to overcome the
MDR. One was the increased aqueous solubility of the
drug, enabling use of the drug without adding surfactants
(e.g., cremophore EL). The investigators also observed a
high drug concentration near the injection site because of
the increased adherence of CPP-drug to the surrounding
tissues. Although this property might not be favorable for
systemic administration of the CPP-drug, it can improve
therapeutic efﬁcacy of the drug in case of direct intratumor
injection.
For enhanced cytotoxicity and targeted delivery of the
anticancer drug, Lee et al. synthesized a chitosan/doxorubi-
cin/TAT hybrid by chemically conjugating doxorubicin and
TAT to the polymeric chitosan backbone. Compared with
free doxorubicin or chitosan/doxorubicin without TAT, the
chitosan/doxorubicin/TAT hybrid displayed more efﬁcient
cell internalization and, thereby, yielded signiﬁcantly higher
antitumor effects. This enhanced cell internalization of the
chitosan/doxorubicin/TAT hybrid could further alter the
biodistribution proﬁles of the doxorubicin, resulting in aug-
mented tumor localization and eventually leading to signiﬁ-
cant inhibition of tumor growth in CT26 xenograft bearing
mice.71 In addition, Myrberg et al. designed a chimeric pep-
tide by coupling a breast tumor homing peptide (so-called
“PEGA peptide;” 9-mer cyclic peptide: cCPGPEGAGC) with a
CPP (pVEC) and then chemically conjugated this peptide to
an anticancer drug, chlorambucil.72 In vitro studies showed
higher cellular uptake and cytotoxicity level of PEGA-pVEC-
chlorambucil conjugate against breast cancer cells, than
chlorambucil alone. Further, in vivo studies proved that ﬂuo-
rescence dye-labeled PEGA-pVEC could target the vessels of
breast tumors with lower accumulation in nontumor tissues,
compared with pVEC alone. This study exempliﬁes a rational
design for targeted delivery of CPP-coupled drugs. However,
caution must be taken when applying targeting ligands with
a CPP, as previous studies showed that CPP-mediated
uptake was so efﬁcient that it could abolish targeting speci-
ﬁcity of the conjugated antibodies.73 In addition, Shokolenko
et al. reported that the order of the targeting ligands and
CPPs could affect the targeting efﬁciency of chimeric
peptides.74
Not only CPP modiﬁcation could enhance cellular inter-
nalization, but remarkably it could also augment the deliv-
ery of cargoes across the blood brain barrier (BBB) without
compromising its integrity. Rousselle et al. showed that CPP
(SynB1 or D-penetratin) modiﬁcation enabled doxorubicin to
bypass the P-glycoprotein-mediated efﬂux from the BBB,
thereby increasing the transport of doxorubicin into brain
parenchyma by 20-fold. Interestingly, CPP modiﬁcation
also altered the tissue distribution proﬁle of doxorubicin.
Notably, compared with free doxorubicin, signiﬁcantly lower
(10-fold lower) concentration of CPP-modiﬁed doxorubicin
was observed in the heart, which could potentially reduce
the cardiotoxicity concerns.75
CPP-coupled delivery of therapeutic peptides or
proteins
Apoptosis is induced by various cellular stresses and this
process is regulated by certain tumor suppressor proteins,
such as p53 or p16. In many human cancers, the tumor sup-
pressor proteins are altered or dysfunctional due to muta-
tions that occur during tumorigenesis.76,77 Therefore,
attempts have been made to treat cancer by restoring func-
tions of these proteins by means of delivering the full length
proteins or peptides that correspond to the crucial residues
of these proteins.
Snyder et al. constructed a retro-inverso analog of TATp-
p53 C-terminus chimeric peptide.78 Tested against a termi-
nal peritoneal carcinomatosis mouse model by intraperito-
neal (i.p.) injection, the treatment group (mean survival
time: >70 days) showed 6-fold increase of lifespan over
mutant or vehicle treated mice (mean survival time: 10
days). Also, in a terminal peritoneal lymphoma model, treat-
ment group showed 50% longer in survival time than those
of the control groups (mean survival time for vehicle and
mutant peptide treated groups: 35 and 33 days, respec-
tively); with half of the mice surviving for more than 200
days. Another successful antitumor application was realized
by using a chimeric peptide consisting of p53 peptide from
its mdm-2-binding domain (residues 17–26; named
PNC-28) and penetratin.79 Programmed release of PNC-28
from an osmotic pump implanted under the skin or in the
peritoneal cavity effectively blocked the subcutaneously
(s.c.) or i.p. implanted pancreatic tumor growth in vivo.
In an attempt to restore p16 activity, Hosotani et al. pre-
pared “Trojan p16” peptide, which was a disulﬁde bridged
conjugate consisting of 20 amino acid residues of the p16
protein and penetratin, and then tested the efﬁcacy against
a pancreatic tumor animal model.80 In both s.c. or i.p.
implanted tumors, the Trojan p16-treated groups exhibited
a signiﬁcant inhibition of tumor growth (treatment group:
796 17 mg vs. control vehicle only: 1396 15 mg vs. p16
only: 1516 15 mg vs. Trojan peptide only: 149612 mg)
and an improved survival rate (mean survival time beneﬁt
of 6 days for treatment group) over the controls.
Fulda et al. attempted a different approach to induce
apoptosis of tumor cells.81 These investigators prepared a
chimeric peptide consisting of N-terminal 7 amino acid resi-
dues of second mitochondria-derived activator of caspase
(SMAC) and TATp. SMACs are mitochondrial proteins, which
play important roles in mitochondrial regulation of apopto-
sis.82 Induced by apoptotic signals, SMACs are released from
the mitochondria and deactivate the inhibitor of apoptosis
proteins, allowing the apoptosis to proceed. In vitro studies
showed that SMAC-TATp by itself was not effective enough
to kill tumor cells, but could sensitize these cells to apopto-
tic stimuli, such as TNF-related apoptosis inducing ligand
(TRAIL), CD95 or doxorubicin. In an intracranial U87 human
glioma xenograft mouse model, delivery of a combination of
REVIEW ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | FEB 2014 VOL 102A, ISSUE 2 579
SMAC-TATp and TRAIL signiﬁcantly inhibited tumor growth,
and complete eradication of the tumor was observed when
0.6 or 2 mg of TRAIL was administered with the SMAC-TATp.
A rather direct approach being explored to treat cancer
is to deliver highly toxic enzyme drugs into tumor cells.
Because of their repetitive mode of reaction, enzyme drugs
offered an unmatched therapeutic potency over conven-
tional, small cytotoxic drugs, rendering them an attractive
candidate for cancer drug therapy. Gelonin, a plant origin
toxin, which belongs to ribosome inactivating proteins
(RIPs), is highly potent in inhibiting protein translation with
IC50 concentrations being at pico-molar levels.
83 In spite of
this exceptional potency, however, the anticancer activity of
gelonin is rather negligible because it cannot efﬁciently
internalize tumor cells. To overcome this membrane barrier,
Park et al. prepared a chemical conjugate of gelonin with
either TATp or LMWP.20 In cell culture studies, both the
TATp- and LMWP-gelonin conjugates displayed strong anti-
tumor activity when being tested against a mouse model
harboring s.c. murine CT26 colorectal cancer cells. A com-
plete inhibition of tumor growth was observed when the
animals were injected with a total dose of 100 mg of either
CPP-gelonin conjugates.
Apart from gelonin, caspase-3, asparaginase and a proa-
poptotic peptide (KLA; peptide sequence: KLAKLAKKLA-
KLAK) have also been conjugated with CPPs and studied in
vivo. In the respective rat ascite model, acute lymphoblastic
leukemia mouse model and lung carcinoma mouse s.c.
model, CPP-caspase-3, CPP-asparaginase, and CPP-KLA con-
jugates all yielded signiﬁcantly improved survival rates over
those of the control counterparts.29,84,85
CPP-coupled delivery of genes
Delivery of genes, antisense oligodeoxynucleotides (ODNs),
or small interference RNA (siRNAs) could be a powerful
method for cancer therapy.86–88 Indeed, RNA interference
(RNAi) has emerged as a particularly attractive therapeutic
strategy, due to its great speciﬁcity against the target gene
and unmatched tumor-inhibiting efﬁcacy. However, there
remain many obstacles for the delivery of naked siRNA in
vivo. A major hurdle of RNAi treatment lies in the poor cel-
lular permeability of siRNA drugs, due to their strong
charges and relatively large sizes. Various approaches have
been attempted to overcome this obstacle, such as utilizing
cationic liposomes, cationic polymers, or CPPs. Among these
carriers, CPPs have drawn great interest primarily because
of their demonstrated low toxicity under both in vitro and
in vivo conditions.
The two major methods used to attach siRNA to CPP are
via covalent conjugation or noncovalent complex forma-
tion.15 Although covalent conjugation may be the most ideal
approach, it is technically difﬁcult to conjugate and purify
siRNA-CPP because of their strong charge–charge interac-
tions—often leading to the formation of tightly bound com-
plexes and aggregates. Cellular uptake of these ionic siRNA-
CPP aggregates is much poorer comparing to that of the 1:1
siRNA-CPP covalent conjugates, because the exceeding nega-
tive charges of siRNA could easily neutralize the cationic
amino acids of the CPP, rendering both siRNA and CPP to
partially lose their biological functions. Despite such disad-
vantages, noncovalent, ionic complexation of siRNA with
CPP has still been preferably employed in most of the pub-
lished studies, primarily due to its simplicity. While most of
the studies regarding siRNA-CPP have focused on proving
the feasibility under in vitro conditions, the number of
reports demonstrating success in animal models is continu-
ously growing.
Vascular endothelial growth factor (VEGF) plays a major
role in angiogenesis which is essential for the growth of
tumors. Blocking the VEGF receptor (e.g., with an antibody
targeted against the VEGF receptor—Bevacizumab)89 or
silencing the VEGF gene are effective ways to treat can-
cers.90 Kim et al. used cholesterol-R9 conjugate as a carrier
and prepared a complex with siRNA against VEGF
(siVEGF).91 The complex was able to silence the VEGF in
cellular studies and when tested in an s.c. CT26 murine
colon cancer xenograft model, the cholesterol-R9/siVEGF
complex yielded signiﬁcant inhibition in the growth and vas-
cularization of the tumor when compared with the complex
formulated with scrambled siRNA. Another successful appli-
cation of siVEGF/CPP complex was performed by Choi et al.,
who prepared the complex and tested the anticancer activ-
ity in an s.c. SK-HEP1-LUC xenograft mice model.27 The
siVEGF/LMWP complex signiﬁcantly reduced the tumor size,
which was already relatively large (700–750 mm3) when
the treatment was started.
Cyclin B, a mitotic cyclin involved in mitosis by forming
a complex with cyclin-dependent kinase, has also been of
interest for RNAi treatment.92 Essential for cell division,
cyclin B is often deregulated in tumors. Crombez et al. have
prepared a siRNA against cyclin B1 in complex with a trun-
cated version of MPG (named ‘MPG-8).93 The siRNA/MPG-8
complex was able to down-regulate cyclin B1 levels and
induce arrest of the cell cycle, leading to inhibition of the
proliferation of various human cancer cell lines. Further-
more, in an s.c. xenograft tumor model, signiﬁcant inhibition
of tumor growth was observed after intratumor or intrave-
nous (i.v.) injection of the siRNA/MPG-8 complex.
Another attractive target for RNAi-based treatment is
the epidermal growth factor receptor (EGFR), which is fre-
quently altered in various tumors, including high-grade glio-
mas.94 Han et al. tested a complex of plasmid based EGFR
siRNA (psiEGFR) and TATp-polyamidoamine dendrimer con-
jugated bacterial magnetic carrier against U251 glioma xen-
ograft model via intratumor injection.95 The treatment
group showed signiﬁcant inhibition of tumor growth, which
was equivalent to positive control group (lipofectamine
2000/psiEGFR). Michiue et al. devised a fusion peptide com-
posing of a TATp and a double stranded RNA-binding
domain (referred to as PTD-DRBD) that strongly binds to
any double stranded siRNA. This versatile peptide was uti-
lized as a carrier for siRNAs of EGFR and Akt2. In an intra-
cerebral glioblastoma mouse model, these PTD-DRBD/siRNA
complexes induced signiﬁcant tumoricidal activity and led
to increase in longevity.96 Kim et al. prepared a complex of
siRNA against human epidermal growth factor receptor 2
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(HER2) and oligoarginine (R15) and tested the effect in a
SK-COV3 ovarian xenograft tumor model via intratumor
injection.95 Compared with the scrambled siRNA/R15 com-
plex or naked siRNA, the siHER2/R15 complex displayed
signiﬁcant reduction of tumor growth.
CPP-coupled delivery of nanoparticles
Although the translocation mechanisms of CPPs/CPP-car-
goes remain highly elusive, these peptides have been widely
and successfully exploited for enhanced intracellular
delivery of a variety of nanoparticles, such as magnetic
nanoparticles,56,97–101 lipid-based formulations,33,102–107
micelles,108 gold nanoparticles,109,110 quantum dots,111 and
others.112–116 A number of such applications of
CPP-mediated intracellular delivery of nanoparticles have
been summarized in Table I.
In 1999, Josephson et al. ﬁrst reported the conjugation
of CPPs to nanoparticles.97 In this study, TATp was conju-
gated to CLIOs (crosslinked iron oxide particles). The TATp-
CLIO conjugate yielded efﬁcient labeling of cells, offering
the potential to function as a tool for MRI or in magnetic
separation of homed cells in vivo. In all cell lines tested, the
intracellular delivery of TATp-CLIO, with average size of
41 nm and TATp moieties of 6.7/particle, was about
100-fold higher than that of the control group (non-TATp
conjugated CLIOs). Later on, the effect of TATp density on
the particle surface and the sensitivity of MRI detection
were investigated in mouse lymphocytes using different
TATp/CLIO ratios.100 A nonlinear increase proﬁle in cellular
uptake of TATp–CLIO was observed with increasing TATp/
CLIO ratio. Compared with the control, a maximum of about
100-fold increase in cell uptake was achieved using 15
TATps/CLIO particles. Because of the advancement in intra-
cellular uptake by the TATp moieties, cells could be moni-
tored at 100-fold lower concentrations using a higher ratio
of the TATp/CLIO conjugates.
Another successful study regarding to cell labeling by
CPP modiﬁed nanoparticles was reported by Stroh et al.
These investigators prepared TATp-modiﬁed micelles con-
structed with polyethylene glycol-phosphatidyl ethanolamine
(PEG-PE) containing entrapped quantum dots.111 By incuba-
tion of these TATp-modiﬁed micelles with primary bone
marrow lineage-negative cells, the cells could be success-
fully labeled ex vivo. When those quantum dot-labeled cells
were injected through the carotid artery of MCaIV tumor
bearing mice, their recruitment by the tumor vasculature
could be clearly tracked via imaging of the quantum dots.
Modiﬁcation of liposomes with CPPs such as TATp or
penetratin was also proven successful in enhancing intracel-
lular delivery over a variety of cell lines (rat cardiac myo-
cyte H9C2 cells, murine Lewis lung carcinoma cells and
human breast tumor BT20 cells).117 Direct interaction
between CPPs and cell surface appeared to be essential for
the cell entry, as shielding of CPPs severely inhibited the
uptake. Results showed that approximately ﬁve CPPs per
particle were sufﬁcient to enhance the intracellular delivery
TABLE I. Summary of CPP Modified Nanoparticles and Their Cellular Applications
Nanoparticles CPPs Cell Lines and/or Effects Refs
Liposomes TATp, Penetratin,
Octa-arginine
Calu-3, 12- to 17-fold enhanced cell uptake of liposomes 102
TATp COS-7 103
Poly-arginine NCI-H446, A549, SK-MES-1, Enhanced siRNA intracellu-
lar delivery and tumor cell growth inhibition
104
TAT, Penetratin SK-BR-3, MCF-7, HTB 9, ADR, A431,C26, 12-fold increase
of Dox intracellular uptake
33
TATp LLC, BT20, H9C2, Enhanced cell uptake of liposomes 107
CLIO (MION) TATp Mouse lymphocytes, human natural killer, HeLa, human
hematopoietic CD341, mouse neural progenitor
C17.2, human lymphocytes CD41, T-cells, B-cells,
macrophages, stem cells, MRI imaging and magnetic
separation of homed cells
56,97–99
pH sensitive
PEG-polylactic
acid micelles
TATp MCF-7, Enhanced cytotoxicity at acidic environment
(pH<7)
108
Gold nanoparticles TATp Other NLS
peptides
NIH3T3, HepG2, HeLa, hTERT-BJ1, Enhancedcytosolic
and nuclear uptake of particles
109,110
Quantum dot-loaded
micelles
TATp MS1, lineage-negative bone marrow cells, Dynamic
imaging and tracking of labeled cells
111
PEI-PEG-TAT/DNA
nanoplexes
TATp SH-SY5Y, Enhanced gene expression 112
TATp A549, Enhanced gene transfection of lung cells 113
Boron carbide
nanoparticles
TATp EL4, B16F10, Boron neutron capture therapy 114
Dendrimers TATp, Penetratin MDR3T3, MES-SA/Dx5, Enhanced ODN intracellular
delivery
115
Solid lipid
nanoparticles
DimericTATp 16HBE14o-, Enhanced gene transfection 116
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of liposomes. Nevertheless, the efﬁciency in cell uptake of
liposomes was proportional to the density of the conjugated
CPPs. Interestingly, the kinetics of the uptake was depend-
ent upon the type of the CPP and cell lines. Compared with
the TATp–liposomes, which exhibited relatively slow cell
internalization, the penetratin-liposomes internalized into
cells very rapidly and reached the maximum uptake within
1 h.
An attractive application of CPP-modiﬁed nanoparticles
lies in their use as a transfection agent. Combining the high
binding capacity of the nanoparticles and great translocation
ability of CPPs, highly efﬁcient gene transfection is often
observed. Torchilin et al. prepared a noncovalent complex
between TATp-liposomes and DNA.105 Compared with the
commonly used LipotectinV
R
, the TATp-liposome/DNA com-
plex showed a signiﬁcantly higher transfection and lower
cytotoxicity in vitro, when incubated with mouse ﬁbroblast
NIH 3T3 cells and cardiac myocytes H9C2 cells. These com-
plexes also displayed an efﬁcient transfection by means of
intratumor injection. A multifunctional envelope-type nano-
device (MEND), consisting of a condensed DNA core and a
surrounding lipid envelope, was also synthesized for tumor
gene delivery.118 The MEND containing octa-arginine on the
envelope exhibited a 1000-fold higher transfection activity
than the control DNA/(poly-L-lysine/lipid) complex.
Encouraged by the successes in CPPs for intracellular
delivery of various nanoparticles in vitro, there has been ris-
ing interest in the use of CPP-conjugated nanoparticles for
improved delivery of anticancer drugs in vivo. By combined
effects of tumor targeting via enhanced permeability and
retention (EPR) effect and CPP-mediated cell penetration,
these nanoparticles can provide effective means for safer
delivery of potentially toxic anticancer drugs with greater
therapeutic efﬁcacy. Balzeau et al. synthesized a lipid nano-
capsule functionalized with a glioblastoma-speciﬁc CPP
(NFL-TBS.40–63). When paclitaxel was loaded to this CPP-
modiﬁed lipid nanocapsule and administered to GL261
glioma brain tumor bearing mice,119 it showed selective and
efﬁcient penetration into glioblastoma cells and yielded the
best therapeutic effect among all the tested groups in inhibi-
ting tumor growth (75%). Jiang et al. devised a dual-
functional liposome consisting of pH-responsive CPP (R6H4)
and exterior hyaluronic acid coating (readily degradable by
hyaluronidase rich in certain tumor milieu).120 The nega-
tively charged hyaluronic acid coating of the liposome was
intended to mask the positive charge of CPPs during target-
ing and selectively expose the CPPs to tumor cells.
Paclitaxel-loaded dual-functional liposome yielded signiﬁ-
cant tumor size reduction in Heps xenograft tumor mouse
model, which excelled the therapeutic effect by clinically
used TaxolV
R
. In addition, a CPP (F3 peptide)-functionalized
cisplatin-hydrogel nanoparticle (named “F3-Cis-Np”) was
developed and evaluated for ovarian cancer treatment in
both solid and i.p. tumor models.121 The results showed
that F3-Cis-Np sufﬁciently and selectively bound to the
tumor vessels and induced signiﬁcant tumor regression via
antiangiogenesis.
SMART STRATEGIES FOR TUMOR-LOCALIZED DELIVERY OF
CPP-COUPLED CARGOES
Even though CPPs themselves were not reported to produce
toxicity below the level of hundreds of micro-molar concen-
tration, nonspeciﬁc cellular internalization of CPP-coupled
cargoes might result in unexpected toxicity caused by the
cargoes. In an in vivo study, Schwarze et al. reported that
TATp-b-galactosidase fusion protein could be found in vari-
ous organs all over the body, including the brain.122 The
general lack of the target speciﬁcity of CPPs demands that
special considerations must be taken when delivering drugs
with low tissue selectivity. Although the mechanism for CPP
mediated cellular internalization is yet unclear, previous
studies have shown that the initiation of the cell entry
requires the interaction of CPPs with the cell surface glycos-
aminoglycans that are negatively charged. On the basis of
this property, a key motif for achieving selective delivery of
the CPP-drugs would be to utilize a “smart” strategy that
could block the CPP activities during circulation until it
reaches the target site, and then reverse the block at the
target to expose the CPPs so that it could exert the cell pen-
etrating activity locally.
To date, only a few DDS using the above strategy for tar-
geted delivery of CPP-coupled cargoes have been established
and tested in animal models. The blocking of CPPs was usu-
ally achieved by either directly forming complexes between
cationic CPPs and anionic counterparts or by physically
shielding CPPs with PEG chains. Different methods for
reversing the block have been designed, including utilizing
the tumor microenvironment or applying an external trig-
gering agent.
ACPP (Activatable CPP) prodrug strategy
ACPP is a construct developed by Dr. Tsien and coworkers
for selective delivery of CPPs.123–125 The scheme of the con-
struct is depicted in Figure 2. The construct is composed of
a polycationic CPP (r9; nine D-form arginine residues) fused
FIGURE 2. Schematic illustration of ACPPs. CPP is blocked by a polya-
nionic peptide covalently attached via a MMP2/9-cleavable linker.
Cleavage of the linker induces exposure of CPP and enables cell inter-
nalization. Reproduced with permission from Ref. 123. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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with an polyanionic counterpart (e8; eight D-form glutamate
residues) via a peptide linker cleavable only by certain spe-
ciﬁc proteases (MMP-2 or 9) present in the tumors. While
the linker is intact, r9 and e8 form an intramolecular hair-
pin structure that neutralizes the CPP activity of r9. How-
ever, once the linker is cleaved in the presence of MMP-2 or
9, the r9 is dissociated from e8 due to a weakened interac-
tion. Enhanced cellular uptake of ACPP was obvious in 2D
and 3D cell culture models and even in human specimens,
after cleavage of the linker by MMP-2, which was added
externally or secreted from HT1080. In an in vivo study,
investigators found that r9 could induce severe systemic
toxicity with doses above 5 mmol/kg following i.v. injection,
which eventually led to death of mice due to respiratory
failure. However, injection of ACPP produced a much milder
toxicity even with 4-fold of the tolerable dose.
CPP-modiﬁed ATTEMPTS (Antibody targeted triggered
electrically modiﬁed prodrug type strategy)
The ATTEMPTS is a drug delivery strategy utilizing active
targeting and prodrug feature for selective delivery of mac-
romolecules to the disease site.126 The scheme of the DDS is
illustrated in Figure 3. The underlying principle of this DDS
is by forming a plasma-stable tight complex between the
targeting component, the antibody-heparin conjugate, and
the drug component, a CPP-coupled drug. The complex is
formed by electrostatic interaction between the anionic hep-
arin and the cationic CPP. With the complex formation, the
charge of the CPP is reversibly masked by heparin, leading
to an improved antibody targeting as well as plasma stabil-
ity of CPP against endogenous proteases. The drug delivery
strategy works in two steps. In the ﬁrst step, the DDS is
administered and allowed to accumulate in the tumor site
via antibody-mediated targeting. In the second step, prota-
mine is systemically injected as a triggering agent to reverse
heparin inhibition on the CPP, when the tumor to nontumor
concentration ratio of the DDS is optimal. Protamine is a
small cationic protein that has been used clinically as the
antidote for heparin. Because of the stronger binding
between heparin and protamine compared to that between
heparin and the CPP, protamine triggers the release of the
CPP-drug from the DDS, and the CPP-drug is now free to
penetrate through the tumor cell membrane. The feasibility
of the DDS was demonstrated in an in vitro study by Kwon
et al.126 On the basis of the confocal microscopy and FACS
results, cell uptake of LMWP-asparaginase conjugate was
shown to be effectively blocked by heparin, and this block-
age was successfully reversed by the addition of protamine.
Further studies are currently ongoing in Yang’s lab by utiliz-
ing an anti-CEA antibody for targeting colorectal cancer and
TATp modiﬁed-gelonin.
Reversal shielding by pH-sensitive PEG
A modiﬁed DoxilV
R
-based nanocarrier (doxorubicin-loaded
PEGylated liposome) was reported recently.127 This strategy
was by incorporating a 2C5 monoclonal antibody with long-
protective PEG chains as well as short PEG chains linked with
TATp; both were linked via the pH-responsive hydrazone
FIGURE 3. Schematic diagram of the CPP-modified ATTEMPTS delivery system. Reproduced with permission from Ref. 126. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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bond. Compared with the unmodiﬁed, commercial DoxilV
R
, this
multifunctional liposomal formulation signiﬁcantly aug-
mented the cytotoxicity and intracellular uptake of the drug,
when being examined against four different cancer cell lines
under the pre-exposure to low pH conditions. Other studies of
multifunctional TATp-coupled liposomes and micelles by uti-
lizing similar strategies were also reported elsewhere.128 At
pH 7.5–8.0, these liposomes or micelles displayed very limited
internalization by either NIH-3T3 or U-87 cells. However, in
contrast, effective internalization into both NIH-3T3 and U-87
cells was achieved after brief incubation (15–30 min) at a low
pH (pH 5.0–6.0) under which the nanocarriers shed their PEG
shielding by hydrolysis of the hydrazone bonds.
TATp-modiﬁed and GFP-loaded liposomes were also pre-
pared and studied in vivo by means of intratumor injec-
tion.129 The administration of liposomes without
pH-degradable PEG coating resulted in very limited transfec-
tion of tumor cells, simply because of the TATp moieties
were being shielded by the PEG chains. As a comparison,
the administration of liposomes with pH-sensitive PEG
showed a much higher transfection of tumor cells. Removal
of the PEG shield by the acidic tumor environment led to
the exposure of TATp on the liposome surface and, as a con-
sequence, yielded much enhanced cellular uptake of the
model gene, pEGFP-N1. The scheme of this approach is illus-
trated in Figure 4.
Tumor speciﬁc protease cleavable PEG shielding
In the tumor microenvironment, the levels of certain enzymes
(so-called tumor speciﬁc proteases) such as MMP-2 or 9 are
often elevated in the extracellular space of the tumors. This
upregulated enzyme activity provides a unique strategy to
expose CPP molecules conjugated on the surface of nanopar-
ticles selectively to tumor cells, by masking the nanoparticles
with PEG chains that are cleavable by these tumor speciﬁc
proteases. Harris et al. prepared a magnetic nanoparticle con-
jugated with PEG chains via MMP-2 cleavable peptide linkers
and polyarginine peptides (NH2-RRRRGRRRRK(FITC)GC).101
When the veiled polyarginines under the PEG chains were
exposed by cleavage of the PEG chains via MMP-2, 40-fold
higher cell accumulation of nanoparticles were observed in
vitro. The in vivo feasibility of this system was further con-
ﬁrmed by MRI and ﬂuorescence imaging. The scheme of this
approach is also depicted in Figure 4.
CONCLUSION
CPPs have been exploited in a wide variety of theranostic
applications, including the intracellular delivery of small
anticancer drugs, macromolecules, and nanoparticle sys-
tems. Although the mechanism of CPP translocation remains
unclear, new CPPs including modiﬁcation of existing CPPs
are being designed and tested, which will no doubt extend
the therapeutic applications of CPPs. The potential of CPPs
to deliver highly potent and highly speciﬁc macromolecular
drugs is of particular interest. The ability of CPPs to enter
cells of almost any type, however, still possesses signiﬁcant
toxicity concerns that must be appropriately addressed. To
overcome such toxicity issues, different types of “smart”
strategies have been designed to activate the CPPs only
within diseased tissues. Although it may be too early to pre-
dict clinical applications of CPP-cargoes, the current achieve-
ments in the CPP-mediated delivery of drugs in vivo are
inspiring, and the future of CPP-based effective and safe
chemotherapy indeed looks very promising.
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